Gubra A/S Share Price

Equities

GUBRA

DK0062266474

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen 08:50:00 20/06/2024 pm IST 5-day change 1st Jan Change
436 DKK +14.14% Intraday chart for Gubra A/S +34.15% +248.80%

Financials

Sales 2022 199M 28.65M 2.39B Sales 2023 205M 29.46M 2.46B Capitalization 2.04B 293M 24.46B
Net income 2022 4M 575K 48.04M Net income 2023 -44M -6.32M -528M EV / Sales 2022 * -
Net cash position 2022 2.52M 362K 30.29M Net cash position 2023 386M 55.46M 4.64B EV / Sales 2023 8.05 x
P/E ratio 2022 *
-
P/E ratio 2023
-42.6 x
Employees 220
Yield 2022 *
-
Yield 2023
-
Free-Float 30.58%
More Fundamentals * Assessed data
Dynamic Chart
1 day+14.14%
1 week+34.15%
Current month+32.93%
1 month+44.37%
3 months+30.15%
6 months+251.61%
Current year+248.80%
More quotes
1 week
332.00
Extreme 332
436.00
1 month
298.00
Extreme 298
436.00
Current year
114.00
Extreme 114
436.00
1 year
83.45
Extreme 83.45
436.00
3 years
83.45
Extreme 83.45
436.00
5 years
83.45
Extreme 83.45
436.00
10 years
83.45
Extreme 83.45
436.00
More quotes
Managers TitleAgeSince
Founder 56 01/08/01
Chief Executive Officer 45 01/16/01
Director of Finance/CFO 46 01/22/01
Members of the board TitleAgeSince
Director/Board Member 58 01/22/01
Director/Board Member 48 01/22/01
Founder 50 01/08/01
More insiders
Date Price Change Volume
20/24/20 436 +14.14% 117,841
19/24/19 382 +0.79% 72,020
18/24/18 379 +7.67% 68,382
17/24/17 352 +6.67% 77,345
14/24/14 330 +1.54% 41,243

Delayed Quote Nasdaq Copenhagen, June 20, 2024 at 08:50 pm IST

More quotes
Gubra A/S is a Denmark-based biotechnology company specialized in high-end pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases. The Company’s operations are anchored around its advanced technology platforms and utilization of automation, robotization and digitalization, including machine learning (ML) and artificial intelligence (AI). The Company's business activity are divided into two segments: The CRO Segment offers specialized profitable pre-clinical contract research services at attractive margins within metabolic and fibrotic disease areas such as diabetes, obesity, chronic kidney disease; and The Discovery and Partnership Segment is based on an internal target and drug discovery engine for identification and design of peptide-based drug partnering candidates within metabolic and fibrotic diseases.
Calendar
More about the company